Welcome to the ANTIFREAZE-F trial website
The Anti-Freaze-F trial is looking at the feasibility of conducting a large randomised controlled trial to assess whether an intra-articular injection of anti-TNF (Adalimumab) can reduce pain and improve function in people with pain predominant early-stage frozen shoulder.
We aim to recruit 84 men and women from across England with early stage Frozen shoulder (usually within the first 3 months of experiencing symptoms).
Frozen shoulder is a common condition affecting approximately 9% of people aged 25-64 years. During the early phase the pain is usually unbearable and the later restriction in movement is severely limiting. It occurs when the flexible tissue (capsule) that surrounds the shoulder joint becomes inflamed, thickened and tight. It's not fully understood why this happens but it is more common in people with diabetes or Dupuytren's disease, which causes the fingers to curl into the palm. It can also occur following shoulder injury or surgery. The pain can be very severe and lasts 3-9 months, followed by a 4-12 month period of increasing stiffness, after which the condition usually improves. Frozen shoulder often affects a person’s ability to sleep, carry out everyday activities, and work.
February 2022:
Anti-Freaze-F has now closed to recruitment
December 2022:
British Dupuytren's Society and Diabetes UK feature Anti-Freaze-F
September 2022:
Fourth site open to recruitment is East Sussex Healthcare NHS Trust
August 2022:
Third site open to recruitment is Sandwell and West Birmingham NHS Trust
July 2022:
First participant recruited at University Hospitals Birmingham
May 2022:
First site open to recruitment is United Lincolnshire Hospitals
Second site open to recruitment is University Hospitals Birmingham
January 2022:
The Anti-Freaze-F Trial received REC, MHRA and HRA Approvals in December 2021.
